Teleflex is selling its critical care, interventional urology and original equipment manufacturer (OEM) businesses in two separate deals totaling more than $2 billion as part of the company’s broader portfolio optimization strategy.
UK-based Intersurgical is acquiring Teleflex’s critical care and interventional urology business lines for $530 million. Meanwhile, Teleflex’s OEM business is being acquired by private equity firms Montagu and Kohlberg in a delisting deal valued at around $1.5 billion.
Teleflex’s products within the segments include intermittent catheters in urology and airway management systems in intensive care, while its OEM business focuses on the assembly of tools used in areas such as catheter-based interventions and surgical applications.
Investor sentiment regarding the latest actions appears positive. Following the announcement of the divestitures on December 9, Teleflex shares on the New York Stock Exchange (NYSE) rose almost 10% to a close of $131.25 per share, up from $119.82 the previous day. Teleflex has a market capitalization of $5.8 billion.
Both deals are expected to close in the second half of 2026, pending customary regulatory approvals and other closing conditions.
According to Teleflex CEO Liam Kelly, the sales are expected to establish the company as a leader in “more focused” medical technologies, with complementary businesses in vascular, interventional and surgical access, and a simplified global operating model and manufacturing footprint.
“In addition, following these transactions, Teleflex will have greater flexibility to invest in innovation and compete in these priority markets,” Kelly added.
Plans to focus on the areas mentioned by Kelly appear to be confirmed in Teleflex’s latest financial statements. In the nine months ended September 28, 2025, the majority of Teleflex’s revenue came from the aforementioned business segments. And for Teleflex’s OEM and interventional urology lines, profits declined 11% and 13.9%, respectively, compared to the same period in 2024, suggesting a waning focus. What remains unclear, however, is what effect the sales will have on Teleflex’s previously announced intention to split its business in two.
In February 2025, Teleflex announced plans to split its business into two independently traded entities, with a completion date set for mid-2026. At the time, the company said the business lines now being sold would be grouped into a new standalone business called Teleflex NewCo, with Teleflex’s vascular, interventional and surgical access businesses grouped into a new entity called RemainCo.
Medical Device Network has contacted Teleflex to comment on its prospects for the mooted Teleflex NewCo business.